Results 41 to 50 of about 1,426 (171)
The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease
, 2023 Thyroid Eye Disease (TED) is a vision threatening condition caused by inflammatory damage to the periocular tissue. Teprotumumab is an IGF-1R antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated ...
Shwetha Mudalegundi; Peng Huang; Amanda Henderson; Andrew Carey
core
, 2022 Teprotumumab (TEPEZZA), an insulin-like growth factor-1 receptor inhibitor was shown to improve proptosis, diplopia, and inflammation in thyroid eye disease (TED).
Kimberly Cockerham; Shayna Melvani; Pamela Rakestraw
core
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
Advanced Science, Volume 13, Issue 4, 19 January 2026.This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source
Emerging therapies in the medical management of thyroid eye disease
Frontiers in Ophthalmology, 2023 IntroductionThyroid eye disease (TED) is an immune-mediated disorder associated with a heterogenous array of manifestations that may unfavorably impact vision and quality of life.
Alisha Kamboj +3 more
doaj +1 more source
Case Reports in Ophthalmological Medicine, Volume 2026, Issue 1, 2026.Introduction Orbital myopathy is a condition involving the extraocular muscles, and establishment of a differential diagnosis is crucial to determine its etiology. However, the broad spectrum of the etiologies and the overlap in their clinical and radiological findings often make the diagnosis challenging.
Daisuke Shinohara +3 more
wiley +1 more source
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source
Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results
, 2021 Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improves proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients.1,2 In the phase 3, randomized, placebo-controlled trial ...
Raymond S, Douglas; Saba Sile; Terry J. Smith; George J. Kahaly
core
Should I Have Teprotumumab or Surgery?
, 2023 Pathophysiology of thyroid eye disease/thyroid orbitopathy and teprotumumab: In orbitopathy, it is believed that there is a cross reaction of thyroid auto-antibodies with the thyrotropin receptor (TSHR) and the insulin growth factor receptor (IGFR) on ...
Alison V. Crum
core +2 more sources
Precision Medicine in Graves’ Disease and Ophthalmopathy
Frontiers in Pharmacology, 2021 Graves’ disease (GD) is a condition caused by an autoimmune process involving the thyroid gland, whose main outcome is hyperthyroidism. TSAb start the autoimmune process stimulating the overproduction of thyroid hormones.
Giusy Elia +9 more
doaj +1 more source
Advanced Science, Volume 12, Issue 45, December 4, 2025.This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng +14 more
wiley +1 more source